Alzheimer's Disease Trial, Recruiting NCT06313944 Sponsor: Heinrich-Heine University, Duesseldorf Condition: Alzheimer's Disease
Back to Alzheimers Disease

Alzheimer's Disease Trial, Recruiting

NCT06313944
Recruiting Not Applicable

Who may be able to join

AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI

Who might be able to join this trial:

  • You are between 18 and 85 years old
  • You have shown a gradual decline in memory that has been getting worse over more than six months, and this affects your ability to carry out everyday tasks
  • You have had a brain scan (MRI), and if possible, additional tests such as spinal fluid (CSF) analysis or a PET scan to look for signs linked to Alzheimer's disease — though these extra tests are optional
  • You are receiving treatment at a specialist neurology or psychiatry centre where the therapy can be properly supervised

Who may not be able to join:

  • You have significant brain conditions unrelated to Alzheimer's disease, such as severe blood vessel damage in the brain, brain tumours, abnormal blood vessels in the brain, or a specific condition affecting brain blood vessels called CAA (confirm with trial site)
  • You are currently pregnant
  • You have metal implants in your body
  • You are currently receiving or have recently received antibody therapy for Alzheimer's disease (confirm with trial site)
  • You have a blood clotting disorder or are taking blood-thinning medication
  • You have epilepsy
  • You have any other health condition that might make it difficult for you to follow the trial's requirements

Important: Always verify eligibility with the trial site directly before applying.

Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.

This is a simplified plain English summary of the eligibility criteria. Full criteria are set by the trial investigators and may include additional requirements not shown here. Never self-exclude from a trial based on this summary. Contact the trial site directly to confirm your eligibility.
Last synced 21 July 2026
This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.

Contact this trial

Principal Investigator: Lars Wojtecki, Prof. Dr., Heinrich-Heine-Universität

Phone: +492118106756

Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.

GP referral letter

Print a one-page summary to share with your doctor.

Trial details

Status
Recruiting
Phase
Not Applicable
Sponsor
Heinrich-Heine University, Duesseldorf
Registry
ClinicalTrials.gov
Start date
6 August 2025
Est. completion
1 October 2026

Where this trial is recruiting

🇩🇪 Germany

Primary endpoints

Number of (Serious) Adverse Events; Number of adverse device effects

Can't join this trial?

Expanded access pathways

If this trial is not available to you, other access pathways may exist. In Australia, the TGA Special Access Scheme allows access to unapproved therapeutic goods for individual patients.

TGA Special Access Scheme information

Find other recruiting trials on ClinicalTrials.gov

Data last synced from ClinicalTrials.gov: 21 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.

Trial recruitment status can change without notice between our nightly data updates. Always contact the trial site directly to confirm current recruitment status before making any decisions or travel arrangements.

View original record on ClinicalTrials.gov